Your browser is no longer supported. Please, upgrade your browser.
Settings
MRTX Mirati Therapeutics, Inc. daily Stock Chart
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.96 Insider Own0.60% Shs Outstand32.48M Perf Week27.33%
Market Cap2.10B Forward P/E- EPS next Y-4.02 Insider Trans-80.45% Shs Float32.17M Perf Month56.18%
Income-88.00M PEG- EPS next Q-0.86 Inst Own- Short Float17.44% Perf Quarter52.18%
Sales9.50M P/S221.55 EPS this Y33.70% Inst Trans0.29% Short Ratio7.50 Perf Half Y32.38%
Book/sh6.94 P/B9.34 EPS next Y-26.00% ROA-42.70% Target Price64.33 Perf Year161.82%
Cash/sh7.47 P/C8.68 EPS next 5Y- ROE-46.80% 52W Range23.10 - 65.35 Perf YTD52.76%
Dividend- P/FCF- EPS past 5Y1.50% ROI- 52W High-0.83% Beta1.87
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low180.46% ATR3.84
Employees51 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)86.37 Volatility9.46% 8.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-29.90% Profit Margin- Rel Volume1.31 Prev Close63.71
ShortableYes LT Debt/Eq0.00 EarningsFeb 05 BMO Payout- Avg Volume748.54K Price64.80
Recom1.80 SMA2043.95% SMA5055.44% SMA20045.01% Volume982,852 Change1.71%
Dec-03-18Initiated B. Riley FBR Buy $60
Oct-29-18Upgrade Guggenheim Neutral → Buy
Jul-09-18Reiterated Oppenheimer Outperform $35 → $62
Mar-12-18Initiated Barclays Overweight $44
Jan-09-18Reiterated H.C. Wainwright Buy $17 → $21
Nov-14-17Upgrade Leerink Partners Mkt Perform → Outperform
Oct-12-17Resumed H.C. Wainwright Buy $20
Sep-19-17Initiated Oppenheimer Outperform $18
Sep-15-17Reiterated Leerink Partners Mkt Perform $7 → $9
Nov-17-16Initiated H.C. Wainwright Buy $12
Jun-06-16Reiterated Wedbush Outperform $29 → $27
Jun-06-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-06-16Downgrade Jefferies Buy → Hold
May-24-16Reiterated Wedbush Outperform $41 → $29
May-09-16Reiterated Wedbush Outperform $45 → $41
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $32
Feb-17-16Resumed Jefferies Buy
Jan-13-16Upgrade Citigroup Neutral → Buy
Nov-23-15Initiated Citigroup Neutral
Oct-19-15Initiated Barclays Overweight $50
Jan-15-19 04:21PM  Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor PR Newswire
07:55AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics ACCESSWIRE
Jan-10-19 06:00AM  Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause ACCESSWIRE +13.27%
Jan-09-19 08:39AM  Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4% Zacks +5.46%
Jan-07-19 08:30AM  Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®) PR Newswire +7.31%
Jan-02-19 04:30PM  Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference PR Newswire +5.26%
Dec-20-18 04:42PM  Mirati Therapeutics Added To NASDAQ Biotechnology Index PR Newswire
Dec-12-18 03:27AM  Hedge Funds Are Buying Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Dec-10-18 04:15PM  Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors PR Newswire
Dec-04-18 07:20AM  Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar Discovering Underlying Factors of Influence GlobeNewswire
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
Nov-29-18 05:20PM  Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849 PR Newswire -5.56%
Nov-20-18 04:30PM  Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-09-18 08:35AM  Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting PR Newswire -5.65%
08:30AM  Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting PR Newswire
Nov-08-18 04:32PM  Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors PR Newswire
Nov-07-18 09:00AM  Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference PR Newswire +6.95%
Nov-06-18 06:52PM  Mirati: 3Q Earnings Snapshot Associated Press
04:15PM  Mirati Therapeutics Reports Third Quarter Financial Results PR Newswire
Nov-05-18 04:15PM  Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting PR Newswire
Oct-30-18 09:00AM  Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer PR Newswire +6.11%
Oct-25-18 08:50AM  Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.50%
Oct-22-18 04:49PM  Mirati Shares Fall After Cancer Trial Progress Report TheStreet.com -15.00%
04:45PM  Biotech Dives After Lung Cancer Regimen With Bristol Disappoints Investor's Business Daily
04:26PM  These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests Investor's Business Daily
11:51AM  Why Mirati Therapeutics Inc. Is Plunging Today Motley Fool
10:37AM  Mirati Therapeutics stock drops 19.5% after cancer trial results MarketWatch
06:10AM  Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial PR Newswire
Oct-21-18 05:10AM  Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress PR Newswire
Oct-15-18 04:30PM  Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call PR Newswire
Oct-09-18 09:41AM  3 Biotech Stocks With Major Incoming Catalysts Motley Fool
Oct-08-18 05:29PM  Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy Zacks
Sep-14-18 11:15AM  Mirati Therapeutics Inc (NASDAQ:MRTX): Time For A Financial Health Check Simply Wall St.
Aug-29-18 04:30PM  Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference PR Newswire
Aug-24-18 07:11AM  Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar? Zacks
Aug-16-18 04:30PM  Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition PR Newswire
Aug-01-18 06:53PM  Mirati: 2Q Earnings Snapshot Associated Press
04:15PM  Mirati Therapeutics Reports Second Quarter Financial Results PR Newswire
09:15AM  Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar? Zacks
Jul-28-18 08:00AM  How to Invest in Clinical-Stage Biotechs Without Losing Money Motley Fool
Jul-24-18 04:59PM  Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress PR Newswire
Jul-17-18 07:35AM  Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks ACCESSWIRE +5.11%
Jun-25-18 04:30PM  Mirati Therapeutics Added to Russell 2000® Index PR Newswire
Jun-15-18 09:20AM  Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar? Zacks
Jun-11-18 04:15PM  Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-07-18 11:26AM  Here's Why Mirati Therapeutics, Inc. Is Rising Today Motley Fool +18.40%
08:00AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jun-06-18 04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
May-31-18 04:30PM  Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting PR Newswire
May-30-18 04:46PM  Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference PR Newswire
May-29-18 08:44AM  Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session Zacks
May-07-18 05:03PM  Mirati: 1Q Earnings Snapshot Associated Press
04:10PM  Mirati Therapeutics Reports First Quarter Financial Results PR Newswire
May-02-18 12:01PM  Harry Boxers four biotech stocks to watch today MarketWatch
Apr-30-18 04:47PM  Can These Top-Performing Biotech Stocks Keep Climbing? Motley Fool
Apr-26-18 11:19AM  Harry Boxers two biotechnology stocks to watch today MarketWatch
Apr-24-18 04:15PM  Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials PR Newswire
Mar-09-18 08:26AM  Did Mirati Therapeutics Incs (NASDAQ:MRTX) Recent Earnings Growth Beat The Trend? Simply Wall St. +11.79%
Mar-08-18 04:30PM  Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results PR Newswire
Mar-07-18 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
Feb-21-18 07:35AM  Recent Analysis Shows EchoStar, Toro, Genesee & Wyoming, Express Scripts Holding, D.R. Horton, and Mirati Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-08-18 04:15PM  Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference PR Newswire -10.52%
Jan-11-18 10:54AM  Nektar Notches New Highs As Stock Triples In Two Months Forbes +6.67%
Jan-10-18 11:39AM  Harry Boxers three health-care stocks to watch today MarketWatch +14.17%
Jan-08-18 06:00AM  BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region GlobeNewswire -8.02%
Nov-20-17 04:15PM  Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire +5.80%
Nov-16-17 07:06PM  Cramer's lightning round: After Opko Health's quarter, it... CNBC Videos +35.23%
08:45AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Nov-15-17 04:01PM  Mirati Therapeutics Announces Proposed Public Offering Of Common Stock PR Newswire +6.44%
Nov-13-17 04:15PM  Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs PR Newswire
Nov-08-17 08:30AM  Market Trends Toward New Normal in ONEOK, ServiceNow, Mirati, ImmunoCellular, United Technologies, and USG Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-02-17 05:49AM  Mirati reports 3Q loss Associated Press +7.09%
Nov-01-17 04:30PM  Mirati Therapeutics Reports Third Quarter 2017 Financial Results PR Newswire
Oct-18-17 12:52PM  Four Biotech And Health Care Breakouts Forbes
Oct-12-17 04:45PM  Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients PR Newswire
03:32PM  4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate Benzinga
Sep-19-17 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
01:31PM  A Peek Into The Future For Mirati Therapeutics Benzinga
Sep-18-17 08:45AM  Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock Zacks
03:00AM  Mirati Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Sep-15-17 12:07PM  Is It Too Late To Buy Mirati Therapeutics Inc (MRTX)? Simply Wall St. +135.79%
10:42AM  Mirati Therapeutics Sitravatinib Data, Explained Benzinga
09:24AM  Mirati Skyrockets On Positive Data - Biotech Movers TheStreet.com
08:27AM  Mirati Therapeutics' stock soars on heavy volume after positive cancer treatment trial results MarketWatch
Sep-14-17 04:30PM  Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer PR Newswire
Sep-06-17 02:00PM  Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer PR Newswire
Aug-30-17 04:15PM  Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Citi Biotech Conference PR Newswire
Aug-21-17 08:15AM  Mirati Therapeutics (MRTX) Rises: Stock Moves 10.9% Higher Zacks
Aug-03-17 07:09PM  Mirati reports 2Q loss Associated Press
04:05PM  Mirati Therapeutics Reports Second Quarter 2017 Financial Results PR Newswire
Jul-18-17 08:30AM  Mirati Therapeutics (MRTX) Rises: Stock Moves 11.5% Higher Zacks
Jul-05-17 04:15PM  Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York PR Newswire
Jun-27-17 04:05PM  Mirati Therapeutics Announces Appointment Of Neil Reisman To The Board Of Directors PR Newswire -7.41%
May-31-17 04:15PM  Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference PR Newswire -9.68%
May-04-17 06:38PM  Mirati reports 1Q loss Associated Press
04:05PM  Mirati Therapeutics Reports First Quarter 2017 Financial Results PR Newswire
Mar-27-17 04:05PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
Mar-15-17 01:04PM  MIRATI THERAPEUTICS, INC. Financials +6.67%
Mar-09-17 06:46PM  Mirati reports 4Q loss Associated Press
04:22PM  MIRATI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reisman Neil10% OwnerJan 11Option Exercise12.8925,972334,68739,103Jan 15 09:15 PM
Boxer Capital, LLC10% OwnerJan 09Option Exercise0.00150,0031501,565,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 09Sale51.55150,0007,732,1001,415,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 08Option Exercise0.00550,0125501,565,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 08Sale52.10550,00028,657,0721,015,560Jan 09 09:31 PM
Davis Aaron I.DirectorJan 08Sale52.8010,000528,00037,052Jan 09 09:31 PM
Davis Aaron I.DirectorJan 07Sale46.4040,0001,855,80347,052Jan 09 09:31 PM
Christensen JamieEVP, Chief Scientific OfficerDec 26Option Exercise17.415,16989,9928,789Dec 28 07:00 PM
BAUM CHARLES MPresident & CEOAug 24Option Exercise17.4111,486199,97162,418Aug 24 07:00 PM
BAUM CHARLES MPresident & CEOAug 23Option Exercise8.5051,810440,385102,742Aug 24 07:00 PM
BAUM CHARLES MPresident & CEOAug 23Sale57.5551,8102,981,78850,932Aug 24 07:00 PM
CHEN ISANEVP, Chief Medical OfficerJul 16Option Exercise20.911,86739,03234,582Jul 17 07:00 PM
Christensen JamieSVP, Chief Scientific OfficerJun 27Option Exercise5.504,99927,4958,393Jun 28 07:00 PM
Christensen JamieSVP, Chief Scientific OfficerJun 27Sale49.544,999247,6653,394Jun 28 07:00 PM
Christensen JamieSVP, Chief Scientific OfficerJun 26Option Exercise5.405,20828,1238,085Jun 28 07:00 PM
Christensen JamieSVP, Chief Scientific OfficerJun 26Sale48.765,208253,9653,394Jun 28 07:00 PM
venBio Select Advisor LLC10% OwnerJun 11Buy38.85400,00015,540,0004,798,101Jun 12 01:57 PM
Boxer Capital, LLC10% OwnerJun 07Buy38.85193,0507,499,9931,565,560Jun 11 05:00 PM
CHEN ISANEVP, Chief Medical OfficerApr 25Option Exercise16.9413,038220,81731,836Apr 26 06:07 PM
Donadio Jamie ASr. VP, CFOMar 09Option Exercise17.4112,100210,66112,100Mar 13 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerMar 09Option Exercise21.3922,000470,62024,877Apr 26 06:00 PM
Donadio Jamie ASr. VP, CFOMar 09Sale35.0012,100423,5000Mar 13 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerMar 09Sale33.0022,000726,0402,877Apr 26 06:00 PM
Donadio Jamie ASr. VP, CFOMar 01Option Exercise6.5251,875338,06351,875Mar 02 06:08 PM
Donadio Jamie ASr. VP, CFOMar 01Sale27.1351,8751,407,1450Mar 02 06:08 PM
BAUM CHARLES MPresident & CEOFeb 23Option Exercise8.5051,810440,385100,366Feb 27 06:00 PM
BAUM CHARLES MPresident & CEOFeb 23Sale28.0351,8101,452,45850,932Feb 27 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerFeb 06Option Exercise21.2223,000488,03025,877Feb 08 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerFeb 06Sale30.0023,000690,0002,877Feb 08 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerJan 26Option Exercise5.4012,50067,50015,377Jan 29 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerJan 26Sale26.1112,500326,4232,877Jan 29 06:00 PM